{
  "Clinical Information": [],
  "Patent Information": [],
  "Sequence Information": {
    "ID": "AP04485",
    "Peptide Name": "Chem-KVL (Synthetic AMPs, Val-rich, Leu-rich, XXE, XXA, UCLL1c; Stapled peptides: SCL-1, SCL-2, SCL-3, SCL-4, SCL-5, SCL-6, SCL-7)",
    "Source": "designed, tandem repeat",
    "Family": "Not found",
    "Gene": "Not found",
    "Sequence": "KVLGRLVKVLGRLV",
    "Sequence Length": 14,
    "UniProt Entry": "Ref",
    "Protein Existence": "Not found",
    "Biological Activity": [
      "Anti-Gram+",
      "Gram-"
    ],
    "Target Organism": "Not found",
    "Hemolytic Activity": "Not found",
    "Cytotoxicity": "Not found",
    "Binding Target": "Not found",
    "Linear/Cyclic": "Not found",
    "N-terminal Modification": "Not found",
    "C-terminal Modification": "Not found",
    "Nonterminal Modifications and Unusual Amino Acids": "Not found",
    "Stereochemistry": "Not found",
    "Structure": "Unknown",
    "Structure Description": "Not found",
    "Helical Wheel Diagram": "Not found",
    "PDB ID": "",
    "Predicted Structure": "Not found",
    "Formula": "Not found",
    "Absent Amino Acids": "Not found",
    "Common Amino Acids": "Not found",
    "Mass": "Not found",
    "PI": "Not found",
    "Basic Residues": "Not found",
    "Acidic Residues": "Not found",
    "Hydrophobic Residues": "Not found",
    "Net charge": 4,
    "Boman Index": 0.23,
    "Hydrophobicity": "Not found",
    "Aliphatic Index": "Not found",
    "Half Life": "Not found",
    "Extinction Coefficient Cystines": "Not found",
    "Absorbance 280nm": "Not found",
    "Polar Residues": "Not found",
    "Function": "Not found",
    "Hydrophobic residue%": "57%",
    "Crucial residues": ""
  },
  "Literature Information": {
    "Literature": "Sequence analysis: APD analysis reveals that this sequence is similar (50%) toBombinin H-BO1V=L: 29%, G=K=R: 14%.Activity: active against A. baumannii ATCC 17978 (MIC 16 ug/ml),  S. aureus ATCC 25923 (MIC 16 ug/ml), K. pneumoniae ATCC 13883 (MIC 16 ug/ml), P. aeruginosa ATCC 27853 (MIC 32 ug/ml), E. coli ATCC 25922 (MIC 32 ug/ml), and S. typhimurium clinical isolates (MIC 32 ug/ml).Peptide engineering: introducing one (i, i+4) type staple to the peptide increased peptide helicity and stability in serum. Of note, these staples increased peptide activity primarily against S. aureus and P. aeruginosa with MIC as low as 4 ug/ml.",
    "Author": "Zhen B, Geng C, Yang Y, Liang H, Jiang Y, Li X, Ye G.2024",
    "Reference": "Bioorg Med Chem Lett. 2024 May 10:129794. doi: 10.1016/j.bmcl.2024.129794.PubMed",
    "Title": "Systematic alanine and stapling mutational analysis of antimicrobial peptide Chem-KVL"
  },
  "3D Structure": []
}